Ear-Zap device could ease nerve woes in kidney patients

NCT ID NCT06927024

Recruiting now Symptom relief Sponsor: NYU Langone Health Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This pilot study tests whether a device that gently stimulates a nerve in the ear (taVNS) is safe and tolerable for people with chronic kidney disease stages 3-5 who have autonomic nervous system dysfunction. Thirty participants will use the device daily for two weeks. The main goals are to see if people can complete the sessions and if serious side effects like abnormal heart rates occur.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: transcutaneous auricular vagus nerve stimulation (taVNS) device
What this could lead to: If it works, this could point toward a drug-free way to improve autonomic nerve function in people with chronic kidney disease.
What could go wrong: This is a very small, early pilot study with only 30 participants, focused mainly on safety and feasibility. It may not show clear benefit, and the device might cause heart rhythm changes or fainting.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC KIDNEY DISEASES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic kidney disease chronic renal failure syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHRONIC KIDNEY DISEASES

Contacts and locations

Locations

NYU Langone Health
RECRUITING

New York, New York, 10016, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.